A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium - Related Studies

A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium

This study has been completed.

Study NCT00035061. Last updated on July 18, 2006. Information provided by Eli Lilly and Company

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Urologic Neoplasms
		Metastases, Neoplasm

2	Additional conditions recognized in this trial
		Carcinoma, Transitional Cell
		Neoplasm Metastasis
		Neoplasms

3	More general conditions related to this trial
		Carcinoma
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Neoplastic Processes
		Pathologic Processes
		Urogenital Neoplasms

4	Interventions listed in this trial
		pemetrexed

5	More general drug interventions related to this trial
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Enzyme Inhibitors
		Folic Acid Antagonists
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		Eli Lilly and Company